Ozempic, Other Drugs Selected for Maryland Pricing Review (1)

Maryland’s prescription drug affordability review board is looking at whether to set health plan payment limits for the blockbuster diabetes drug Ozempic, along with other products from companies that have sued the Biden administration over Medicare price negotiations.

Novo Nordisk A/S‘s Ozempic, approved to lower blood sugar levels and reduce the risk of heart attack and other conditions in adults with Type 2 diabetes, is one of eight drugs the Maryland Prescription Drug Affordability Board plans to send to the state’s stakeholder council for further affordability review, according to an agenda for the board’s March 25 meeting.

Maryland’s PDAB, ...